Intravitreal ketorolac for the treatment of chronic cystoid macular edema after cataract surgery
Authors Tsilimbaris M, Tsika C, Kymionis G
Received 29 September 2015
Accepted for publication 6 November 2015
Published 12 February 2016 Volume 2016:12 Pages 177—182
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Garry Walsh
Miltiadis K Tsilimbaris, Chrysanthi Tsika, George D Kymionis
Department of Ophthalmology, University of Crete, Heraklion, Greece
Purpose: To report two cases of chronic postoperative cystoid macular edema, resistant to topical therapy, treated with consecutive intravitreal injections of ketorolac tromethamine.
Methods: Four daily intravitreal injections of 500 µg/0.05 mL of ketorolac were given to each patient. Complete clinical examination and OCT were performed before every injection, 1, 2, 3 weeks, and 1, 3, and 6 months after the last injection. Fluorescein angiography was performed at baseline examination, 1, 3, and 6 months after the last injection.
Results: In both cases, the edema regressed and visual acuity increased. At 6 months after the last injection, the leakage was significantly reduced at the fluorescein angiography.
Discussion: Both cases responded favorably to the consecutive intravitreal administration of ketorolac tromethamine. The long-lasting remission of the macular edema in these chronic cases underlines the therapeutic potential of these agents when delivered intravitreally.
Keywords: postoperative CME, intravitreal, ketorolac, NSAIDs
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]